SBS-101
/ Skyline Biosci
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
October 19, 2021
This Study is to Evaluate the Safety and Pharmacokinetics of SBS-101 in Patients With Oral Premalignant Lesions
(clinicaltrials.gov)
- P1; N=0; Withdrawn; Sponsor: Skyline Biosciences; N=24 ➔ 0; Not yet recruiting ➔ Withdrawn
Clinical • Enrollment change • Trial withdrawal • Oral Cancer • CRP
October 26, 2020
This Study is to Evaluate the Safety and Pharmacokinetics of SBS-101 in Patients With Oral Premalignant Lesions
(clinicaltrials.gov)
- P1; N=24; Not yet recruiting; Sponsor: Skyline Biosciences; Trial completion date: Apr 2021 ➔ May 2023; Trial primary completion date: Apr 2021 ➔ Apr 2023
Clinical • Trial completion date • Trial primary completion date • Oral Cancer
May 08, 2020
This Study is to Evaluate the Safety and Pharmacokinetics of SBS-101 in Patients With Oral Premalignant Lesions
(clinicaltrials.gov)
- P1; N=24; Not yet recruiting; Sponsor: Skyline Biosciences; Trial completion date: Nov 2020 ➔ Apr 2021; Trial primary completion date: Nov 2020 ➔ Apr 2021
Clinical • Trial completion date • Trial primary completion date
1 to 3
Of
3
Go to page
1